EGFRviii Antikörper (AA 1-50)
-
- Target Alle EGFRviii (EGFRv3) Produkte
- EGFRviii (EGFRv3) (EGFR vIII (EGFRv3))
-
Bindungsspezifität
- AA 1-50
- Reaktivität
- Human
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser EGFRviii Antikörper ist unkonjugiert
- Applikation
- Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), ELISA, Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
- Kreuzreaktivität
- Huhn, Human, Maus
- Aufreinigung
- Purified by Protein A.
- Immunogen
- KLH conjugated synthetic peptide derived from human EGFRvIII
- Isotyp
- IgG
-
-
- Applikationshinweise
-
WB 1:100-1000
IHC-P 1:100-500
IF(IHC-P) 1:50-200 - Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 1 μg/μL
- Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- 4 °C,-20 °C
- Informationen zur Lagerung
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
- Haltbarkeit
- 12 months
-
-
The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer." in: Oncotarget, Vol. 8, Issue 5, pp. 7666-7677, (2018) (PubMed).
: "F25P preproinsulin abrogates the secretion of pro-growth factors from EGFRvIII cells and suppresses tumor growth in an EGFRvIII/wt heterogenic model." in: Cancer letters, Vol. 380, Issue 1, pp. 1-9, (2016) (PubMed).
: "EGFL7 is an intercellular EGFR signal messenger that plays an oncogenic role in glioma." in: Cancer letters, Vol. 384, pp. 9-18, (2016) (PubMed).
: "EGFRvIII/integrin β3 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis." in: Oncotarget, Vol. 7, Issue 4, pp. 4680-94, (2016) (PubMed).
: "PET imaging of glioblastoma multiforme EGFR expression for therapeutic decision guidance." in: American journal of nuclear medicine and molecular imaging, Vol. 5, Issue 4, pp. 379-89, (2015) (PubMed).
: "Potentials and capabilities of the Extracellular Vesicle (EV) Array." in: Journal of extracellular vesicles, Vol. 4, pp. 26048, (2015) (PubMed).
: "An optical probe for noninvasive molecular imaging of orthotopic brain tumors overexpressing epidermal growth factor receptor." in: Molecular cancer therapeutics, Vol. 11, Issue 10, pp. 2202-11, (2012) (PubMed).
: "
-
The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer." in: Oncotarget, Vol. 8, Issue 5, pp. 7666-7677, (2018) (PubMed).
-
- Target
- EGFRviii (EGFRv3) (EGFR vIII (EGFRv3))
- Abstract
- EGFRv3 Produkte
- Hintergrund
-
Synonyms: EGFR vIII, EGFRvIII, Epidermal growth factor receptor variant type _, epidermal growth factor receptor isoform a variant, ERBB, HER1, ERBB1, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, EGFR
Background: Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin. Isoform 2 may act as an antagonist of EGF action.
- Gen-ID
- 1956
- UniProt
- Q59FL8
-